Updated:
Mayewell Capital
Mayewell Capital is an investment firm focused on healthcare, pharmaceuticals, and biotechnology. It has made two investments, including a Bridge investment in...
Overview
Mayewell Capital is an investment firm focused on healthcare, pharmaceuticals, and biotechnology. It has made two investments, including a Bridge investment in ThirtyFiveBio on April 15, 2025.
General information
Firm type
Generalist
Location
Region
North America
Country
United States
City
Bryn Mawr
Corporate office
Bryn Mawr, PA, United States
Principals
John Zhu
Founder, President, CIO, and Managing Member
Sector focus
Frequently asked questions
Who runs investment decisions at Mayewell Capital?
John Zhu, the firm's Founder, President, CIO, and Managing Member, runs investment decisions. He is the sole named investment principal in firm communications. W. Wong is listed as a business partner through official corporate channels, though no specific investment role has been disclosed publicly.
How is Mayewell Capital related to Ingenio Therapeutics?
John Zhu serves simultaneously as CEO and Founder of Ingenio Therapeutics, a separate operating company, while managing Mayewell Capital. The relationship is not formally structured as a family office or captive venture arm — the two entities share a common founder but operate under distinct corporate identities. This dual role gives Mayewell a diligence mechanism rooted in operating experience within the therapeutics sector.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: